CODX Overview

Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.

Wall Street analysts forecast CODX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CODX is1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Co-Diagnostics Inc revenue for the last quarter amounts to 263.92K USD, increased 76.74

Co-Diagnostics Inc. EPS for the last quarter amounts to -13.67 USD, increased 27.52

Co-Diagnostics Inc (CODX) has 115 emplpoyees as of May 11 2026.

Today CODX has the market capitalization of 9.11M USD.